It's about time. An approval next year would not do too much damage to ongoing P3 trial, which by the way is quite risky imo (TDM1 head-to-head against Trastuzumab + chemo). Timely for a much needed secondary offering.
Will Roche take out IMGN to save 6% royalty? Other than TDM1, the real bright spot for IMGN is the forehead of that Mad Money entertainer who gainfully read whatever script the puppet master fed him.
Market Data 
Markets 
AI
